7 days ago · These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe ...
Missing: myelogenous | Show results with:myelogenous
Sep 24, 2024 · This phase I trial studies the side effects, best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia (AML) that has ...
Missing: lymphocyte | Show results with:lymphocyte
Sep 25, 2024 · Measurable residual disease (MRD) is strongly associated with risk of relapse and long-term survival outcomes in patients with acute myeloid leukemia (AML).
Missing: chronic myelogenous decides
Sep 19, 2024 · First-in-human phase 1/2 study of the menin-mll inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: updated results from dose escalation.
Sep 26, 2024 · This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL.
Sep 16, 2024 · Meanwhile, the novel agents have led to improved outcomes for patients with relapsed/refractory cHL, leading to questions about the timing and role of stem cell ...
Missing: myelogenous decides
Sep 20, 2024 · SARCLISA is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd ...
Missing: chronic myelogenous
Sep 9, 2024 · In this review, we explore the current landscape of CAR-T cell manufacturing and discuss some of the challenges limiting production capacity worldwide.
Missing: myelogenous decides
Sep 29, 2024 · Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment for relapsed/refractory B-cell lymphomas.
Missing: myelogenous decides
Sep 23, 2024 · This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see ...
